X4 pharmaceuticals announces ema validation of marketing authorization application (maa) for mavorixafor for the treatment of whim syndrome

Submission supported by positive results from global, phase 3 4whim clinical trial; u.s. regulatory approval in whim syndrome granted in 2024 decision on maa expected in 1h 2026 boston, jan. 24, 2025 (globe newswire) -- x4 pharmaceuticals (nasdaq: xfor), a company driven to improve the lives of people with rare diseases of the immune system, today announced that its marketing authorization application (maa) for mavorixafor for the treatment of whim syndrome (warts, hypogammaglobulinemia, infections and myelokathexis), a rare primary immunodeficiency, has been validated for review and is now under evaluation with the european medicines agency's (ema) committee for medicinal products for human use (chmp). the ema previously granted orphan designation to mavorixafor in whim syndrome.
MAA Ratings Summary
MAA Quant Ranking